Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis.
Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB. Jaeckle KA, et al. Among authors: lesser g. J Neurooncol. 2002 May;57(3):231-9. doi: 10.1023/a:1015752331041. J Neurooncol. 2002. PMID: 12125986 Clinical Trial.
Low-grade gliomas.
Ruiz J, Lesser GJ. Ruiz J, et al. Curr Treat Options Oncol. 2009 Aug;10(3-4):231-42. doi: 10.1007/s11864-009-0096-2. Epub 2009 Apr 19. Curr Treat Options Oncol. 2009. PMID: 19381819 Review.
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Lee EQ, et al. Neuro Oncol. 2020 May 15;22(5):601-612. doi: 10.1093/neuonc/noaa015. Neuro Oncol. 2020. PMID: 31974566 Free PMC article.
Efficacy of osimertinib against EGFRvIII+ glioblastoma.
Chagoya G, Kwatra SG, Nanni CW, Roberts CM, Phillips SM, Nullmeyergh S, Gilmore SP, Spasojevic I, Corcoran DL, Young CC, Ballman KV, Ramakrishna R, Cross DA, Markert JM, Lim M, Gilbert MR, Lesser GJ, Kwatra MM. Chagoya G, et al. Among authors: lesser gj. Oncotarget. 2020 Jun 2;11(22):2074-2082. doi: 10.18632/oncotarget.27599. eCollection 2020 Jun 2. Oncotarget. 2020. PMID: 32547705 Free PMC article.
275 results